← Leaderboards
Celine Gelinas
Univ Of Med/Dent Nj-R W Johnson Med Sch
$4,408,045
Attributed
$4,514,417
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $386.2K · FY2005–25$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,514,417 · 4
By mechanism
R01$3,529,205 · 2
R33$772,468 · 1
R25$212,744 · 1
Top collaborators
- Lauren M Aleksunes2 shared
Most similar at Univ Of Med/Dent Nj-R W Johnson Med Sch
Same institution · by research overlap
- Michael J Leibowitz$7,369,215
- Joseph Dougherty$6,079,984
Others in their field
Top investigators on “Nuclear Factor Kappa Beta”
- Inder Mohan Verma · Salk Institute For Biological Studies$6,196,441
- Dongsheng Cai · University Of Wisconsin-Madison$5,730,216
- Albert Sidney Baldwin · University Of North Carolina Chapel Hill$5,313,928
- Yvonne M.w. Janssen-Heininger · University Of Vermont &St Agric College$5,184,302
- Michael Karin · University Of California, San Diego$5,001,646
- Sergei S Makarov · University Of North Carolina Chapel Hill$4,154,279
Research focus
Nuclear Factor Kappa BetaApoptosisLymphomaResponseSite Directed MutagenesisPathway InteractionsRegulationCell DifferentiationPhosphorylationNeoplasm /Cancer GeneticsMulticatalytic Endopeptidase ComplexBcl2 Gene /ProteinBiological Signal TransductionB LymphocyteOncoproteinsCarcinogenesisGenetically Modified AnimalsGenetic TranscriptionLaboratory MouseChickensAffectCellsGene Induction /RepressionInsight
Grant awards (19)
5/6 NJ ACTS: A Platform for Translational Science in New Jersey: CTSA R25 at Rutgers, Biomedical Health Sciences$106,372
R25 · FY2025 · TR · contact PI
5/6 NJ ACTS: A Platform for Translational Science in New Jersey: CTSA R25 at Rutgers, Biomedical Health Sciences$106,372
R25 · FY2024 · TR · contact PI
Specific activation of latent HIV-1 by inhibiting E3 ubiquitin ligase activity$386,234
R33 · FY2018 · AI · contact PI
Specific activation of latent HIV-1 by inhibiting E3 ubiquitin ligase activity$386,234
R33 · FY2017 · AI · contact PI
Functional analysis of Bfl-1/A1 in apoptosis and oncogenesis$183,634
R01 · FY2011 · CA · contact PI
Functional analysis of Bfl-1/A1 in apoptosis and oncogenesis$58,188
R01 · FY2010 · CA · contact PI
Functional analysis of Bfl-1/A1 in apoptosis and oncogenesis$247,664
R01 · FY2009 · CA · contact PI
Functional analysis of Bfl-1/A1 in apoptosis and oncogenesis$247,822
R01 · FY2008 · CA · contact PI
Trans acting function of the v and c Rel oncoproteins$265,220
R01 · FY2005 · CA
Trans acting function of the v and c Rel oncoproteins$265,383
R01 · FY2004 · CA
THE NF KAPPAB SIGNALING PATHWAY, APOPTOSIS AND CANCER$242,045
R01 · FY2004 · CA
Trans acting function of the v and c Rel oncoproteins$265,542
R01 · FY2003 · CA
THE NF KAPPAB SIGNALING PATHWAY, APOPTOSIS AND CANCER$242,045
R01 · FY2003 · CA
Trans acting function of the v and c Rel oncoproteins$265,696
R01 · FY2002 · CA
THE NF KAPPAB SIGNALING PATHWAY, APOPTOSIS AND CANCER$242,045
R01 · FY2002 · CA
Trans acting function of the v and c Rel oncoproteins$265,845
R01 · FY2001 · CA
THE NF KAPPAB SIGNALING PATHWAY, APOPTOSIS AND CANCER$242,045
R01 · FY2001 · CA
THE NF KAPPAB SIGNALING PATHWAY, APOPTOSIS AND CANCER$264,545
R01 · FY2000 · CA
TRANS-ACTING FUNCTION OF THE V- AND C-REL ONCOPROTEINS$231,486
R01 · FY2000 · CA